Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy

PURPOSE: Prostate-specific antigen (PSA) kinetics, and more specifically a ≥ 30% decline in PSA within 3 months after initiation of first-line chemotherapy with docetaxel, are associated with improvement in overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). Th...

詳細記述

保存先:
書誌詳細
主要な著者: Halabi, Susan, Armstrong, Andrew J., Sartor, Oliver, de Bono, Johann, Kaplan, Ellen, Lin, Chen-Yen, Solomon, Nicole C., Small, Eric J.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2013
主題:
ORIGINAL REPORTS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3805930/
https://ncbi.nlm.nih.gov/pubmed/24101043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.50.3201
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料